Logo image of LSL-DB.CA

LSL Pharma Group Inc (LSL-DB.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:LSL-DB -

100 CAD
0 (0%)
Last: 5/6/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to LSL-DB. LSL-DB was compared to 3 industry peers in the Personal Care Products industry. LSL-DB has a bad profitability rating. Also its financial health evaluation is rather negative. LSL-DB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LSL-DB had negative earnings in the past year.
LSL-DB had a negative operating cash flow in the past year.
LSL-DB.CA Yearly Net Income VS EBIT VS OCF VS FCFLSL-DB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

LSL-DB has a Return On Assets (-4.37%) which is in line with its industry peers.
LSL-DB has a Return On Equity (-8.14%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -4.37%
ROE -8.14%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LSL-DB.CA Yearly ROA, ROE, ROICLSL-DB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

LSL-DB has a Gross Margin (25.13%) which is in line with its industry peers.
LSL-DB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 25.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSL-DB.CA Yearly Profit, Operating, Gross MarginsLSL-DB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 -20 -40 -60 -80

More info and screens

3

2. Health

2.1 Basic Checks

LSL-DB does not have a ROIC to compare to the WACC, probably because it is not profitable.
LSL-DB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LSL-DB.CA Yearly Shares OutstandingLSL-DB.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 200K 400K 600K 800K
LSL-DB.CA Yearly Total Debt VS Total AssetsLSL-DB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 5K 10K 15K 20K 25K

2.2 Solvency

An Altman-Z score of 393.87 indicates that LSL-DB is not in any danger for bankruptcy at the moment.
LSL-DB has a Altman-Z score of 393.87. This is amongst the best in the industry. LSL-DB outperforms 100.00% of its industry peers.
LSL-DB has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.45, LSL-DB is doing good in the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 393.87
ROIC/WACCN/A
WACC7.66%
LSL-DB.CA Yearly LT Debt VS Equity VS FCFLSL-DB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 -2M -4M -6M -8M

2.3 Liquidity

LSL-DB has a Current Ratio of 1.17. This is a normal value and indicates that LSL-DB is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.17, LSL-DB is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
A Quick Ratio of 0.50 indicates that LSL-DB may have some problems paying its short term obligations.
With a Quick ratio value of 0.50, LSL-DB is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.5
LSL-DB.CA Yearly Current Assets VS Current LiabilitesLSL-DB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 50K 100K 150K 200K 250K

More info and screens

0

3. Growth

3.1 Past

LSL-DB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.11%.
EPS 1Y (TTM)-17.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSL-DB.CA Yearly Revenue VS EstimatesLSL-DB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2M 4M 6M 8M 10M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSL-DB. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSL-DB.CA Price Earnings VS Forward Price EarningsLSL-DB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, LSL-DB is valued a bit cheaper than 75.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10620.58
LSL-DB.CA Per share dataLSL-DB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LSL-DB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LSL Pharma Group Inc

TSX-V:LSL-DB (5/6/2025, 7:00:00 PM)

100

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners23.12%
Ins Owner ChangeN/A
Market Cap11.55B
Revenue(TTM)15.82M
Net Income(TTM)-1.66M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 730.22
P/FCF N/A
P/OCF N/A
P/B 567.19
P/tB 1028.67
EV/EBITDA 10620.58
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.14
BVpS0.18
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.37%
ROE -8.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 25.13%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA 8.35
Cap/Depr 206.6%
Cap/Sales 16.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.5
Altman-Z 393.87
F-ScoreN/A
WACC7.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.44%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2755.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

LSL Pharma Group Inc / LSL-DB.CA FAQ

What is the ChartMill fundamental rating of LSL Pharma Group Inc (LSL-DB.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to LSL-DB.CA.


What is the valuation status of LSL Pharma Group Inc (LSL-DB.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to LSL Pharma Group Inc (LSL-DB.CA). This can be considered as Overvalued.


How profitable is LSL Pharma Group Inc (LSL-DB.CA) stock?

LSL Pharma Group Inc (LSL-DB.CA) has a profitability rating of 1 / 10.


What is the financial health of LSL Pharma Group Inc (LSL-DB.CA) stock?

The financial health rating of LSL Pharma Group Inc (LSL-DB.CA) is 3 / 10.